-
Mashup Score: 0New CML Treatment Shows Promise, But Standard Therapy Endures - 6 hour(s) ago
The ASC4FIRST trial explores asciminib for chronic myeloid leukaemia, but experts question its design and outcomes, suggesting imatinib remains the preferred first-line therapy.
Source: www.emjreviews.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 4
Discover important insights into the clonal evolution of blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive blood cancer.
Source: www.emjreviews.comCategories: General Medicine News, Onc News and JournalsTweet
The ASC4FIRST trial has shown a promising alternative to TKIs for chronic myeloid leukaemia. Explore the trial: https://t.co/L44CrarKOD #Hematology #MedicalResearch #Healthcare